Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.

Circulation - 29 Nov 2005

Straczek Céline, Oger Emmanuel, Yon de Jonage-Canonico Marianne Beau, Plu-Bureau Geneviève, Conard Jacqueline, Meyer Guy, Alhenc-Gelas Martine, Lévesque Hervé, Trillot Nathalie, Barrellier Marie-Thérèse, Wahl Denis, Emmerich Joseph, Scarabin Pierre-Yves

Abstract excerpt

BACKGROUND: Oral estrogen increases the risk of venous thromboembolism (VTE) in postmenopausal women, particularly in those with a prothrombotic mutation. Transdermal estrogen may be safe with respect to VTE. We investigated the impact of the route of estrogen administration on the association be...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Estrogens
Share to Factor V

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hormone Replacement Therapy

Share to Postmenopause

Share to Prothrombin

Share to Thromboembolism

Share to Thrombophilia

Share to Venous Thrombosis

Source

Identifiers

PMID: 16301339
DOI: 10.1161/CIRCULATIONAHA.105.565556

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16301339-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration.PMID 16301339Read ↗

Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis.Semantic proximity Read ↗

Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease.Semantic proximity Read ↗

Synergism between oral estrogen therapy and cytochrome P450 3A5*1 allele on the risk of venous thromboembolism among postmenopausal women.Semantic proximity Read ↗

Estrogen receptor alpha polymorphism and venous thromboembolism in male and female: data from the EDITH study.Semantic proximity Read ↗

HORMONE EXPOSURE AND VENOUS THROMBOEMBOLISM IN COMMERCIALLY-INSURED WOMEN 50 TO 64 YEARS OF AGESemantic proximity Read ↗

Risk factors for venous thromboembolism in pre-and postmenopausal women.Semantic proximity Read ↗

The effect of prothrombotic blood abnormalities on risk of deep vein thrombosis in users of hormone replacement therapy: a prospective case-control study.Semantic proximity Read ↗

Risks and benefits of estrogen therapy for a male-to-female transsexual with a prothrombin gene mutation.Semantic proximity Read ↗

Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives.Semantic proximity Read ↗

Factor V Leiden, prothrombin G20210A substitution and hormone therapy: indications for molecular screening.Semantic proximity Read ↗

Thrombotic risk during oral contraceptive use and pregnancy in women with factor V Leiden or prothrombin mutation: a rational approach to contraception.Semantic proximity Read ↗

Oral contraceptives and venous thromboembolism: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.